• 1 Prior Art and the Law
  • 1.1 Prior Art in the US Patent Law
    • 1.1.1 § 102. Conditions for patentability; novelty and loss of right to patent
    • 1.1.2 § 103. Conditions for patentability; non-obvious subject matter
  • 1.2 Prior Art in the European Patent Convention
    • 1.2.1 Article 54 - Novelty
    • 1.2.2 Article 56 - Inventive step
• 2 Weblinks
  • 2.1 Concrete Laws
  • 2.2 Discussions and general info about those Laws

Prior Art is defined under the terms of novelty and state of the art

(TITLE 35 > PART II > CHAPTER 10 > § 102)

A person shall be entitled to a patent unless—

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent, or

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of the application for patent in the United States, or

© he has abandoned the invention, or

(d) the invention was first patented or caused to be patented, or was the subject of an inventor’s certificate, by the applicant or his legal representatives or assigns in a foreign country prior to the date of the application for patent in this country on an application for patent or inventor’s certificate filed more than twelve months before the filing of the application in the United States, or

(e) the invention was described in

• (1) an application for patent, published under section 122 (b), by another filed in the United States before the invention by the applicant for patent or
• (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351 (a) shall have the effects for the purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language; [1] or

(f) he did not himself invent the subject matter sought to be patented, or

(g)

• (1) during the course of an interference conducted under section 135 or section 291, another inventor involved therein establishes, to the extent permitted in section 104, that before such person’s invention thereof the invention was made by such other inventor and not abandoned, suppressed, or concealed, or
• (2) before such person’s invention thereof, the invention was made in this country by another inventor who had not abandoned, suppressed, or concealed it. In determining priority of invention under this subsection, there shall be considered not only the respective dates of conception and reduction to practice of the invention, but also the reasonable diligence of one who was first to conceive and last to reduce to practice, from a time prior to conception by the other.

TITLE 35 > PART II > CHAPTER 10 > § 103

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

(b)

• (1) Notwithstanding subsection (a), and upon timely election by the applicant for patent to proceed under this subsection, a biotechnological process using or resulting in a composition of matter that is novel under section 102 and nonobvious under subsection (a) of this section shall be considered nonobvious if—

• (A) claims to the process and the composition of matter are contained in either the same application for patent or in separate applications having the same effective filing date; and
• (B) the composition of matter, and the process at the time it was invented, were owned by the same person or subject to an obligation of assignment to the same person.
• (2) A patent issued on a process under paragraph (1)—

• (A) shall also contain the claims to the composition of matter used in or made by that process, or
• (B) shall, if such composition of matter is claimed in another patent, be set to expire on the same date as such other patent, notwithstanding section 154.
• (3) For purposes of paragraph (1), the term “biotechnological process” means—

• (A) a process of genetically altering or otherwise inducing a single- or multi-celled organism to—

• (i) express an exogenous nucleotide sequence,
• (ii) inhibit, eliminate, augment, or alter expression of an endogenous nucleotide sequence, or
• (iii) express a specific physiological characteristic not naturally associated with said organism;
• (B) cell fusion procedures yielding a cell line that expresses a specific protein, such as a monoclonal antibody; and
• (C) a method of using a product produced by a process defined by subparagraph (A) or (B), or a combination of subparagraphs (A) and (B).

© Subject matter developed by another person, which qualifies as prior art only under one or more of subsections (e), (f), and (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

(1) An invention shall be considered to be new if it does not form part of the state of the art.

(2) The state of the art shall be held to comprise everything made available to the public by means of a written or oral description, by use, or in any other way, before the date of filing of the European patent application.

(3) Additionally, the content of European patent applications as filed, of which the dates of filing are prior to the date referred to in paragraph 2 and which were published under Article 93 on or after that date, shall be considered as comprised in the state of the art.

(4) Paragraph 3 shall be applied only in so far as a Contracting State designated in respect of the later application, was also designated in respect of the earlier application as published.

(5) The provisions of paragraphs 1 to 4 shall not exclude the patentability of any substance or composition, comprised in the state of the art, for use in a method referred to in Article 52, paragraph 4, provided that its use for any method referred to in that paragraph is not comprised in the state of the art.

An invention shall be considered as involving an inventive step if, having regard to the state of the art, it is not obvious to a person skilled in the art. If the state of the art also includes documents within the meaning of Article 54, paragraph 3, these documents are not to be considered in deciding whether there has been an inventive step.

• Law: U.S. Code collection, Title 35 - Patents
• Law: European Patent Convention

• Wikipedia: United States patent law
• Wikipedia: European patent law
• Wikipedia: European Patent Convention

<< back